ArticleEndocrine oncology (Bristol, England)2025
Cytologically non-malignant thyroid nodules with three or more high-risk genetic mutations have poor outcomes.
Article in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While traditional risk stratification for thyroid cancer primarily focused on tumor pathology, molecular profiling is increasingly recognized for its clinical relevance. There are limited data on tumors with three or more mutations, especially when presenting with non-malignant cytology. This study aims to evaluate the clinical behavior of cytologically non-malignant thyroid nodules with three or more potent oncogenic mutations. Methods: Electronic medical records of patients at our institution with thyroid nodules who underwent molecular testing were reviewed to identify cases with cytologically benign or indeterminate thyroid nodules that harbored three or more oncogenic mutations. Clinical, cytological, and molecular data were analyzed to assess tumor behavior. Results: Four of six cases were histologically malignant at index surgery. One histologically benign case developed distant metastases 7 years later. Retrospective analysis of the two histologically benign cases and the one case with low-risk histology demonstrated significant intratumoral heterogeneity. The benign case that developed distant metastases was found to have an area of intratumoral heterogeneity whose genetic profile matched the metastases. Conclusions: Despite bland cytological and ultrasonographic features, these tumors exhibited aggressive behavior. The molecular profile of thyroid cancers should be considered when determining treatment, especially in cases with multiple high-risk mutations, as they may behave more aggressively than predicted by cytology or imaging alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.